LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

• Andrew C. Adams,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Carolyn A. Halstead,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Barbara C. Hansen,

  Affiliation Center for Preclinical Research, University of South Florida, Tampa, Florida, United States of America

  ⨯
• Armando R. Irizarry,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Jennifer A. Martin,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Sharon R. Myers,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Vincent L. Reynolds,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Holly W. Smith,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Victor J. Wroblewski,

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Alexei Kharitonenkov

  * E-mail: a.kharch@lilly.com

  Affiliation Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯